Oncology – Erbitux®, UFT®
Merck Serono focuses on developing novel, cancer-specific therapies that provide beneficial therapeutic outcomes and create
new options for cancer patients. Our monoclonal antibody, Erbitux, specifically blocks the epidermal growth factor receptor
(EGFR) to enhance the effect of chemotherapy and radiotherapy.
Neurodegenerative diseases – Rebif®
Merck Serono is a market leader in the treatment of Multiple Sclerosis (MS) with Rebif®, approved for the treatment of relapsing-remitting
MS in over 80 countries worldwide.
Fertility – GONAL-f®, Ovidrel, Luveris®, Cetrotide®, Crinone®, Pergoveris®
Merck Serono is the world leader in fertility treatment. We offer a broad portfolio of gonadotropin hormones for the treatment
of infertility at different stages of the reproductive cycle, allowing physicians to tailor treatment to individual patient
needs.
Endocrinology – Saizen®, Serostim®, Kuvan®
Merck Serono was a pioneer in making recombinant human growth hormone available for the treatment of growth hormone deficiency
in children and adults (Saizen) and for the treatment of HIV-associated wasting (Serostim). With the recently announced European marketing authorization with Kuvan® (sapropterin dihydrochloride), Merck Serono offers
the only treatment indicated in Europe for the treatment of hyperphenylalaninemia (HPA) due to phenylketonuria (PKU) in patients
over the age of 4; or due to tetrahydrobiopterin BH4 deficiency.
CardioMetabolic Care – Glucophage®, Concor®, Euthyrox®
Merck Serono offers an extensive range of therapeutic options for the integrated management of cardiovascular and metabolic
diseases. These include the Glucophage franchise of oral antidiabetics for the treatment of type 2 diabetes, the beta-blocker
bisoprolol (Concor) and a range of thyroid hormones (Euthyrox).
